Nkarta Q3 net loss $21.7 mln

Nkarta

10/11/2025 21:13

Overview

Nkarta reports Q3 net loss of $21.7 mln

Company has $316.5 mln in cash, funding operations into 2029

NKX019 clinical program progresses with streamlined enrollment and promising B-cell depletion

Outlook

Nkarta expects cash reserves to fund operations into 2029

Company plans to present NKX019 data at a medical conference in 2026

Nkarta streamlines enrollment for Ntrust-1 and Ntrust-2 trials

Result Drivers

RESEARCH AND DEVELOPMENT: R&D expenses were $20.2 million for the third quarter of 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.29
Q3 Net Income
-$21.72 mln
Q3 Basic EPS
-$0.29
Q3 Cash & Investments
$316.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nkarta Inc is $12.00, about 83.7% above its November 7 closing price of $1.96

Press Release: ID:nGNX9ZGbw7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)